Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Antibody clues after stem cell transplants could prevent rejection

NCT ID NCT06395220

First seen Jan 11, 2026 · Last updated Jun 23, 2026 · Updated 25 times

Summary

This completed study looked at 314 people with blood cancers who received stem cell transplants from mismatched donors. Researchers tracked donor-specific antibodies after transplant to see how often they appear and what factors influence them. The goal is to better understand and prevent graft rejection or poor graft function.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HAEMATOLOGICAL MALIGNANCY are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • People's Hospital of Peking University

    Beijing, China

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this research could help doctors better predict and prevent graft rejection or poor graft function after stem cell transplants.

What could go wrong

This is an observational study, not a treatment trial. It aims to gather knowledge, not test a new therapy, so there is no direct benefit to participants.

Conditions

The condition(s) this trial relates to.

hematopoietic and lymphoid system neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.